Literature DB >> 34012602

Optimal therapeutic strategy using durable left ventricular assist device in Korea.

Teruhiko Imamura1.   

Abstract

Entities:  

Year:  2021        PMID: 34012602      PMCID: PMC8107515          DOI: 10.21037/jtd-21-125

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
Lee and colleagues reported the first experience of durable left ventricular assist device (LVAD) implantation before the initiation of Korean national insurance coverage in 2018 (1). I would like to congratulate their successful LVAD therapy with favorable outcomes comparable to those reported in the international registry, despite relatively sick cohort with contraindication of heart transplantation. Several concerns should improve their findings. Because all LVAD implantations were performed before the approval of Korean national insurance, patient profiles were unique (1). Now that medical insurance covers LVAD implantation, optimal patient selection, including preserved end-organ dysfunction and relatively stable hemodynamics assigned to INTERMACS profile 3, might be required to further improve clinical outcomes. As device-related comorbidity, aortic insufficiency is one of the critical and progressive diseases that increase intra-cardiac loading and worsen systemic congestion (2). Repeated trans-thoracic echocardiography or monitoring of HeartWare waveform would be useful for early detection and follow-up of aortic insufficiency (3). The incidence of gastrointestinal bleeding was relatively high (1). Given the low incidence of gastrointestinal bleeding in Japan, we hypothesized that Asian patients might have a genetic resistance to gastrointestinal bleeding (4). Further studies are warranted to investigate the association between genetic type and bleeding complication. Almost half of clinically stable LVAD patients have abnormal hemodynamics, which is associated with device-related comorbidities (5). Our team proposed a hemodynamic ramp test, during which medication and device speed are optimized considering hemodynamic profiles at each device speed, targeting to improve mortality and morbidity. Description of hemodynamic management in their team would strengthen the implication of their report. The article’s supplementary files as
  5 in total

1.  Aortic insufficiency in patients with sustained left ventricular systolic dysfunction after axial flow assist device implantation.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Takeo Fujino; Toshiro Inaba; Hisataka Maki; Masaru Hatano; Osamu Kinoshita; Kan Nawata; Shunei Kyo; Minoru Ono
Journal:  Circ J       Date:  2014-11-07       Impact factor: 2.993

2.  Hemodynamic Ramp Tests in Patients With Left Ventricular Assist Devices.

Authors:  Nir Uriel; Gabriel Sayer; Karima Addetia; Savitri Fedson; Gene H Kim; Daniel Rodgers; Eric Kruse; Keith Collins; Sirtaz Adatya; Nitasha Sarswat; Ulrich P Jorde; Colleen Juricek; Takeyoshi Ota; Valluvan Jeevanandam; Daniel Burkhoff; Roberto M Lang
Journal:  JACC Heart Fail       Date:  2015-12-30       Impact factor: 12.035

3.  Estimation of the Severity of Aortic Insufficiency by HVAD Flow Waveform.

Authors:  Teruhiko Imamura; Nikhil Narang; Daniel Rodgers; Daisuke Nitta; Takeo Fujino; Sara Kalantari; Bryan Smith; Gene Kim; Ann Nguyen; Ben Chung; Luise Holzhauser; Tae Song; Takeyoshi Ota; Valluvan Jeevanandam; Gabriel Sayer; Nir Uriel
Journal:  Ann Thorac Surg       Date:  2019-11-19       Impact factor: 4.330

4.  Use of durable left ventricular assist devices for high-risk patients: Korean experience before insurance coverage.

Authors:  Jun Ho Lee; Ilkun Park; Heemoon Lee; Kiick Sung; Young Tak Lee; Darae Kim; Jeong Hoon Yang; Jin-Oh Choi; Eun-Seok Jeon; Yang Hyun Cho
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

5.  Hemocompatibility-related Adverse Events Following HeartMate II Left Ventricular Assist Device Implantation between Japan and United States.

Authors:  Teruhiko Imamura; Minoru Ono; Koichiro Kinugawa; Norihide Fukushima; Akira Shiose; Yoshiro Matsui; Kenji Yamazaki; Yoshikatsu Saiki; Akihiko Usui; Hiroshi Niinami; Goro Matsumiya; Hirokuni Arai; Yoshiki Sawa; Nir Uriel
Journal:  Medicina (Kaunas)       Date:  2020-03-13       Impact factor: 2.430

  5 in total
  1 in total

1.  What is the optimal therapeutic protocol for using a durable left ventricular assist device in the near future of a developing country?

Authors:  Jun Ho Lee; Yang Hyun Cho
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.